Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2248518 | 0.96 | GGT1 (0.67) | GGT1KMT2AMMP2MMP9LMNA | |
| SCHEMBL3449139 | 0.90 | GGT1 (0.55) | GGT1KMT2AMMP2MMP9TSHR | |
| SCHEMBL2246539 | 0.90 | GGT1 (0.55) | GGT1KMT2AMMP2MMP9TSHR | |
| Hydrochloric Acid SCHEMBL23833980 | 0.89 | GGT1 (0.53) | GGT1KMT2AMMP2MMP9TSHR | |
| Hydrochloric Acid SCHEMBL23833983 | 0.89 | GGT1 (0.53) | GGT1KMT2AMMP2MMP9TSHR | |
| SCHEMBL2246498 | 0.83 | LMNA (0.52) | GGT1KMT2AMMP2LMNATSHR | |
| SCHEMBL16822755 | 0.81 | GGT1 (0.62) | GGT1KMT2ALMNASIGMAR1ALDH1A1 | |
| SCHEMBL16822754 | 0.81 | GGT1 (0.62) | GGT1KMT2ALMNASIGMAR1ALDH1A1 | |
| Bromide SCHEMBL11446589 | 0.81 | MAPT (0.60) | GGT1LMNATSHRSIGMAR1TRPV1 | |
| SCHEMBL461572 | 0.81 | KMT2A (0.54) | GGT1KMT2AMMP2MMP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987131-B1 | Phenylacetic acid compositions for treating or preventing hypercholesterolemia | BURZYNSKI STANISLAW R | 2006-01-17 | — | — | US | claimed |
| EP-1206936-B1 | Phenylacetic acid compositions for treating or preventing hypercholesterolemia | BURZYNSKI STANISLAW R (US) | 2005-08-24 | — | — | EP | claimed |
| EP-1206936-A2 | Phenylacetic acid compositions for treating or preventing hypercholesterolemia | BURZYNSKI, Stanislaw R. (US) | 2002-05-22 | — | — | EP | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
| US-6987131-B1 | Phenylacetic acid compositions for treating or preventing hypercholesterolemia | BURZYNSKI STANISLAW R | 2006-01-17 | — | — | US | disclosed |
| EP-1206936-B1 | Phenylacetic acid compositions for treating or preventing hypercholesterolemia | BURZYNSKI STANISLAW R (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1206936-A2 | Phenylacetic acid compositions for treating or preventing hypercholesterolemia | BURZYNSKI, Stanislaw R. (US) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | GGT1 115/4885KMT2A 2364/4885MMP2 49/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | GGT1 115/4885KMT2A 2364/4885MMP2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.